Appointment of Additional Independent Director w.e.f 13th August, 2025 & Re appointment of Managing Directors.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech's board approved its Q1 FY26 (quarter ended June 30, 2025) financial results, reporting standalone revenue from operations of Rs. 4,649.64 lakhs, up from Rs. 4,311.46 lakhs in the same quarter last year, and net profit of Rs. 616.08 lakhs versus Rs. 569.96 lakhs earlier, taking EPS to Rs. 7.46. On a consolidated basis, net profit stood at Rs. 686.28 lakhs (EPS Rs. 8.30), including Rs. 70.20 lakhs from associates. The board appointed Mr. Debendra Kumar Sabat, a Supreme Court advocate with finance and legal expertise, as an Additional Independent Director. It also approved the re-appointment of both Managing Directors, Mr. Naresh Kumar Singla and Mr. Suresh Chand Singla, for a fresh 5-year term from April 1, 2026 to March 31, 2031, subject to shareholder approval. Additionally, a final dividend of Rs. 2.00 per equity share was recommended, with the record date set as September 19, 2025 and the 33rd AGM scheduled for September 26, 2025.
Modestly positive for shareholders: results show year-on-year revenue and profit growth, the dividend is a steady income signal, and the re-appointment of both MDs signals continuity in leadership. The addition of a new independent director strengthens board composition, though the board remains promoter-family heavy with 7 of 12 directors from the Singla family.